Replimune Group, Inc. - Common Stock (NQ:REPL)

13.07 -0.38 (-2.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

January 21, 2025

PDUFA action date of July 22, 2025, with priority review

From Replimune Group Inc

Via GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2025

From Replimune Group Inc

Via GlobeNewswire

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

January 08, 2025

From Replimune Group Inc

Via GlobeNewswire

Replimune Group: Q3 Earnings Insights ↗

February 08, 2024

Via Benzinga

Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know ↗

December 06, 2023

Via Benzinga

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 23, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Announces Pricing of Upsized Public Offering

November 25, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Announces Proposed Public Offering

November 25, 2024

From Replimune Group Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 22, 2024

Via Benzinga

S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results ↗

November 22, 2024

Via Benzinga

Topics Stocks

Crude Oil Gains Over 1%; Ross Stores Earnings Top Views ↗

November 22, 2024

Via Benzinga

Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday ↗

November 22, 2024

Via Benzinga

Dow Jumps 300 Points; Gap Posts Upbeat Earnings ↗

November 22, 2024

Via Benzinga

Topics Stocks

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

November 21, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 08, 2024

From Replimune Group Inc

Via GlobeNewswire

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 30, 2024

From Replimune Group Inc

Via GlobeNewswire

REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025 ↗

August 08, 2024

REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025.

Via InvestorPlace

Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 07, 2024

Via Benzinga

S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat ↗

June 06, 2024

Via Benzinga

Topics Stocks

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 06, 2024

Via Benzinga

Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗

June 06, 2024

Via Benzinga

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? ↗

June 06, 2024

Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was...

Via Benzinga

J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday ↗

June 06, 2024

Via Benzinga

REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 ↗

May 16, 2024

REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024.

Via InvestorPlace

Crude Oil Moves Lower; AutoZone Profit Tops Views ↗

December 05, 2023

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500...

Via Benzinga

Topics Stocks

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 05, 2023

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 05, 2023

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.